Xenical Research Today is a free monthly online journal that collates and summarizes the latest research about Xenical, including details on orlistat, side-effects, obesity, weight loss, dieting.

The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen.

Garcia SB, da Costa Barros LT, Turatti A, Martinello F, Modiano P, Ribeiro-Silva A, de Oliveira Vespúcio MV, Uyemura SA

Department of Pathology, Ribeirão Preto Medical School, University of São Paulo, USP, Avenida Bandeirantes, 3900, 14049-900 Ribeirão Preto, SP, Brazil.

Orlistat is an anti-obesity agent that increases the fecal fat excretion, which promotes colon carcinogenesis. Therefore, the present study was designed to verify the effects of Orlistat on the formation of rat colonic aberrant crypt foci (ACF) and cell proliferation evaluated by the PCNA method. Male Wistar rats received either a standard diet or a high fat diet (HFD), supplemented or not with Orlistat (200mg/kg chow) and two doses of the carcinogen dimethyl-hydrazine (25mg/Kg). After 30 days, Orlistat was associated to a significant increase in the number of colonic ACFs and cell proliferation in DMH-treated animals, independently of the HFD.

Published 31 July 2006 in Cancer Lett, 240(2): 221-4.
Full-text of this article is available online (may require subscription).

© 2004-2008 Xenical Research Today. All Rights Reserved.